MetaCap

REGENXBIO Statistics

NASDAQ: RGNXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

7.16-0.02 (-0.28%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

REGENXBIO by the numbers

REGENXBIO has a market capitalization of $473.4 million based on 66.12M shares outstanding. With trailing EPS of $-3.20, REGENXBIO is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 4.6% below its 50-day average and 18.5% below its 200-day average.

Average daily trading volume is 1.39M shares, or about $9.9 million in dollar volume.

Summary generated from market data by MetaCap's automated system. Methodology

RGNX valuation vs. peer median

RGNX compared with the median of 8 peer companies
MetricRGNXPeer medianDifference
Market cap$473.44M$469.28M+1%
Avg. volume1.39M390.07K+256%

Peer median across 8 companies: SANA, DNA, FENC, VALN, ETRA, IRLA, PROK, TECX.

Valuation

Market cap
$473.44M
Price / sales (latest FY)
2.78
EPS (TTM)
$-3.20

Price and trading

Previous close
7.18
Open
7.00
Day range
6.86 – 7.30
52-week range
5.46 – 16.19
52-week change
-39.32%
Beta
—
Volume
1.05M

Dividends and events

Annual dividend
None

Additional statistics

Market Cap
473.44M
Forward Pe
-2.33
Eps
-3.20
Dividend Yield
0.00%
Dividend Rate
0.00
Week52 High
16.19
Week52 Low
5.46
Avg Volume
1.39M
Shares Outstanding
66.12M
Ma50
7.51
Ma200
8.79
Earnings Date
Nov 5, 2026
Pct From52w High
-55.78%
Pct From52w Low
31.26%

Related